Showing 1 - 10 of 26
We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level...
Persistent link: https://www.econbiz.de/10014198115
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10014080046
This paper studies the effects of price regulation and parallel imports in the on-patent pharmaceutical market. First, we develop a theory model in which a pharmacy negotiates producer prices with a brand-name firm and then sets retail prices. We show that the effects of price regulation...
Persistent link: https://www.econbiz.de/10013060442
Persistent link: https://www.econbiz.de/10014426057
Persistent link: https://www.econbiz.de/10014430843
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10013285854
Persistent link: https://www.econbiz.de/10010237671
Persistent link: https://www.econbiz.de/10009762378
Persistent link: https://www.econbiz.de/10003604229
Persistent link: https://www.econbiz.de/10011433285